#BCMA
LightNews LightNews
bcma.bsky.social
Did you catch our update on our other platforms? The BCMA has decided to disengage from all Meta platforms, beginning May 16, 2025. Follow us here!
May 9, 2025 at 11:35 PM
erictopol.bsky.social
Our treatments for refractory autoimmune disease keep getting more sophisticated with impressive outcomes.
Here is the first-in-human case of systemic sclerosis treated with engineered NK cells
www.cell.com/cell/fulltex...
An iPSC-derived CD19/BCMA CAR-NK therapy in a patient with systemic sclerosis
This first-in-human use of an iPSC-derived CAR-NK therapy targeting CD19 and BCMA demonstrates safe and marked clinical responses in a patient with severe refractory systemic sclerosis, underscoring t...
www.cell.com
August 7, 2025 at 3:42 PM
sheencr.bsky.social
Ooooh fascinating! Natural killer cells which are early responder so called innate cells could be reprogrammed to tackle severe autoimmune conditions akin to CAR-T cells in cancer #Immunosky 🧪
An iPSC-derived CD19/BCMA CAR-NK therapy in a patient with systemic sclerosis
This first-in-human use of an iPSC-derived CAR-NK therapy targeting CD19 and BCMA demonstrates safe and marked clinical responses in a patient with severe refractory systemic sclerosis, underscoring t...
www.cell.com
July 7, 2025 at 6:56 PM
medicine.stitches.today
A novel BCMA-mRNA vaccine shows promise in effectively targeting and killing multiple myeloma cells, enhancing treatment options.

by Dutta D, Liu J (...) Anderson KC et 7 al. in Blood #MedSky

👉 get more here

📖 read the article:
A BCMA-mRNA vaccine is a promising therapeutic for multiple myeloma
Key Points. We developed a therapeutic cancer vaccine for multiple myeloma against B cell maturation antigen (BCMA).Our findings revealed BCMA-specific imm
ashpublications.org
August 1, 2025 at 8:45 AM
daltmann.bsky.social
Anti-BCMA CAR-T therapy in patients with progressive multiple sclerosis: Cell www.cell.com/cell/fulltex...
Anti-BCMA CAR-T therapy in patients with progressive multiple sclerosis
The first-in-human study of anti-BCMA CAR-T therapy for progressive multiple sclerosis shows a favorable safety profile, depletion of plasma cells in the central nervous system, and alleviation of mic...
www.cell.com
October 17, 2025 at 7:39 AM
newsen.bsky.social
IASO Bio Reveals Groundbreaking Results for First-in-Human BCMA-Therapy in Multiple Myeloma#China#Shanghai#CAR-T_therapy#IASO_Bio#Myeloma_Treatment
IASO Bio Reveals Groundbreaking Results for First-in-Human BCMA-Therapy in Multiple Myeloma
IASO Bio presents promising initial results of IASO206, an innovative in vivo CAR-T therapy targeting BCMA for difficult-to-treat multiple myeloma patients. The data demonstrates an impressive response rate and manageable safety profile.
third-news.com
September 27, 2026 at 3:12 AM
cnes.fr
🤫 Depuis 30 ans, la BCMA du #CNES teste les antennes des #satellites et sondes dans un silence radio parfait 📡✨
Un lieu unique qui garantit que nos missions pourront communiquer avec la Terre une fois dans l’espace.

🔗 À lire : notre article sur cette salle emblématique. cnes.fr/actualites/b...
BCMA : dans les coulisses de 30 ans de tests en télécommunications spatiales | CNES
Au CNES, une pièce spéciale accueille depuis 30 ans les tests des antennes avant leur mission spatiale, pour garantir ensuite la liaison avec satellites et sondes d’exploration. Bienvenue à la BCMA !
cnes.fr
November 18, 2025 at 6:24 PM
bcma.bsky.social
Happy BC Museums Week!

Today, BCMA Interim Executive Director Lorenda Calvert met with Minister Spencer Chandra Herbert to receive the official BC Museums Week Proclamation. Thank you to Minister Herbert for celebrating BC Museums Week today!

#BCMA #BCMuseums #BCMW #BCMuseumsWeek
May 12, 2025 at 9:05 PM
myeloma-society.bsky.social
Jeffrey Matous, MD, shares updates on the TRIlogy-1 trial of ramantamig, a BCMA & GPRC5d trispecific antibody. Response was sustained in pts who switched to Q8W dosing; 2-year PFS was >80% in pts with BCMA/GPRC5d-naïve TCE RRMM. #IMS26
September 24, 2026 at 1:43 PM
myeloma-society.bsky.social
Industry Symposium focused on barriers/challenges and discussed potential solutions, practical operational frameworks for coordinated outpatient delivery of BCMA bispecific antibody therapy in myeloma practice. #IMS26
September 24, 2026 at 11:45 AM
labwaggoner.bsky.social
B cell maturation antigen (BCMA) is dispensable for the survival of long-lived plasma cells @natcomms.nature.com
www.nature.com/articles/s41...
August 3, 2025 at 2:32 AM
delalamo.xyz
An RFdiffusion-generated binder conjugated to a single-chain antibody shows antitumor activity in mouse models www.biorxiv.org/content/10.1...
RF diffusion-based binder design for aiCAR-T cells targeting BCMA. a, Schematic of the RFdiffusion-based forward denoising process used to generate binders (blue) that target the extracellular domain of BCMA (gray). b, Cytotoxicity of ai- and scFv CAR-T against RPMI-8226, MM.1S, and L-363 co-cultured for 16h at various E:T ratios and normalized to the UTD control.
November 27, 2024 at 9:19 AM
drmiguelperales.bsky.social
Application of Stem Cell Boost for Immune Effector Cell Associated Hematotoxicity (ICAHT) Following BCMA Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Multiple Myeloma (MM) #ASH24 #mmsm #CARTCells #medsky ash.confex.com/ash/2024/web...
Paper: Application of Stem Cell Boost for Immune Effector Cell Associated Hematotoxicity (ICAHT) Following BCMA Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Multiple Myeloma (MM)
ash.confex.com
November 18, 2024 at 4:33 AM
adamfeuerstein.bsky.social
Also...

Arcellx won the battle of BCMA CAR-T therapies over Legend Bio

www.statnews.com/2024/12/12/a...
Arcellx won the battle of BCMA CAR-T therapies
Why Arcellx won the battle of BCMA CAR-T therapies against Legend Biotech.
www.statnews.com
December 12, 2024 at 6:28 PM
labwaggoner.bsky.social
Co-infusion of CD19-targeting and BCMA-targeting #CAR-T cells for treatment-refractory systemic #lupus erythematosus: a phase 1 trial @naturemedicine.bsky.social www.nature.com/articles/s41...
September 24, 2025 at 6:06 PM
science.org
Scientists have made major strides in engineering #CARTcell therapies to treat autoimmune disorders such as lupus, according to a 2024 #ScienceTranslationalMedicine Review that discusses recent breakthroughs and clinical trials in the field.

Learn more on #WorldLupusDay: scim.ag/3RTF3HC
(A and B) Approved therapies in liquid tumors target malignant B cells and plasma cells through CD19 and BCMA (A), whereas clinical studies in solid tumors target antigens such as cMET and mesothelin (B). (C and D) In autoantibody-associated autoimmune diseases, such as SLE (C) and MG (D), CARs targeting both CD19 and BCMA are being investigated. Specifically, disease is driven by autoantibodies produced by B cell–derived plasma cells that result in attack of ubiquitous nuclear antigens during SLE and neuromuscular junction antigens during MG.
May 10, 2025 at 2:07 PM
mdanderson.bsky.social
Optimizing pre-CAR T cell therapy may be crucial for improved outcomes in patients with relapsed or refractory multiple myeloma and CNS involvement.

What researchers found with the use of two BCMA-targeting CAR T cell therapies: brnw.ch/21wRyMV #EndCancer
BCMA-directed CAR T cell therapy is safe in patients with relapsed or refractory multiple myeloma and CNS involvement
BCMA-directed CAR T cell therapy is safe in patients with relapsed or refractory multiple myeloma and CNS involvement
brnw.ch
March 25, 2025 at 4:35 PM
katesears.bsky.social
myopenmedicine.com/algorithms/s...
Second relapse multiple myeloma
Treatment algorithm for second relapse multiple myeloma. For BCMA sensitive, approach is similar to first relapse. For second relapse belantamab combinations provide an additional option. Consider sal...
myopenmedicine.com
September 24, 2026 at 3:09 PM
auclairdan.bsky.social
BCMA-directed CAR T-cell therapy in patients with multiple myeloma and CNS involvement ⁦‪⁦‪#MyelomaSky

ashpublications.org/bloodadvance...
March 18, 2025 at 6:14 PM
science.org
A rapid manufacturing pipeline for BCMA-targeting CAR T cells drastically shortens “vein-to-vein” times, and produces cells that demonstrate encouraging safety results in a phase one trial of patients with relapsed #MultipleMyeloma. #ScienceTranslationalMedicine https://scim.ag/4fd3JaW
Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma
Durcabtagene autoleucel, a rapidly manufactured BCMA-directed CAR T cell therapy, was safe and efficacious in relapsed/refractory multiple myeloma.
scim.ag
May 28, 2026 at 3:00 PM
amyloid-planet.bsky.social
BCMA/GPRC5D-dual targeting CART for relapsed #myeloma. The usual CART toxicity, decent response rates, and somehow no skin and/or nail changes. #ASH24
December 10, 2024 at 1:05 AM
myeloma-society.bsky.social
Shari Kaiser, PhD, presents rationale, CAR design approach, preclinical efficacy data & examples of clinical response data in pts with diverse target profiles for investigational BCMA/GPRC5d dual-targeting CAR-T, BMS-986453. #IMS26
September 26, 2026 at 11:55 AM
drmiguelperales.bsky.social
Great presentation by my colleague Heather Landau on transformative results of BCMA #CARTcells for #amyloidosis #tandem26 @mskcancercenter.bsky.social @mskdeptofmed.bsky.social
February 6, 2026 at 4:58 PM
dr-emma-searle.bsky.social
Editorial highlighting a very interesting and informative article. BCMA bispecifics: breaking the chains of resistance
ashpublications.org/blood/articl...
BCMA bispecifics: breaking the chains of resistance
In this issue of Blood, Lee et al1 systematically describe the mechanisms of primary resistance to BCMA×CD3 bispecific antibodies in multiple myeloma and p
ashpublications.org
December 26, 2024 at 8:56 AM
bcma.bsky.social
Exciting transitions at the BCMA! After 5 years of leading our programming team, Lorenda Calvert steps into an Interim Executive director role.

The BCMA Council and staff wish Ryan Hunt all the best in his new role as CEO of the Museum of Vancouver!
April 11, 2025 at 5:01 PM